Joshua D Lee
Joshua D. Lee, MD, MSc
NYU Langone Health - Associate Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
MD, University of Tennessee College of Medicine
MSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice
Joshua D. Lee is an Associate Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails.
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Active
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed


Tofighi B, Sindhu SS, Lee JD, Chemi C, Leonard NR (2020).
Engagement in hepatitis C care continuum among people who use drugs
Journal of Substance Use, 25 (4), 343-349. doi: 10.1080/14659891.2019.1704076.

Tofighi B, Williams AR, Chemi C, Sindhu S, Dickson V, Lee JD (2019).
Patient barriers and facilitators to medications for opioid use disorder in primary care
Substance Use and Misuse, 54 (14), 2409-2419. doi: 10.1080/10826084.2019.1653324. PMCID: PMC6883164.

Tofighi B, Sindhu SS, Chemi C, Lewis CF, Dickson VV, Lee JD (2019).
Perspectives on the HIV continuum of care among adult opioid users in New York City: A qualitative study
Harm Reduction Journal, 16 (1), 58. doi: 10.1186/s12954-019-0329-z. PMCID: PMC6790030.

Velasquez M, Flannery M, Badolato R, Vittitow A, McDonald RD, Tofighi B, Garment AR, Giftos J, Lee JD (2019).
Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
Addiction Science and Clinical Practice, 14 (1), 37. doi: 10.1186/s13722-019-0166-0. PMCID: PMC6771097.

Tofighi B, Lee JD, Sherman S, Schatz D, El-Shahawy O (2019).
Smoking patterns and preferences for technology assisted smoking cessation interventions among adults with opioid and alcohol use disorders
Journal of Substance Use, 24 (6), 660-665. doi: 10.1080/14659891.2019.1642407.


Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP (2016).
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.

Dr. Lee's MyBibliography Profile
Selected Press